032300 — Korea Pharma Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapFalling Star

Annual income statement for Korea Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	71,510	79,577	81,029	83,240	81,277
Cost of Revenue
Gross Profit	34,157	35,903	35,427	36,922	35,174
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	67,743	74,563	74,842	79,302	73,715
Operating Profit	3,766	5,014	6,187	3,939	7,562
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,768	5,208	-1,780	2,014	3,906
Provision for Income Taxes
Net Income After Taxes	3,159	6,368	-1,119	83.8	3,792
Net Income Before Extraordinary Items
Net Income	3,159	6,368	-1,119	83.8	3,792
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,159	6,368	-1,119	83.8	3,792
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	396	584	-108	147	216
Dividends per Share